- Home
- VERU vs XTNT Comparison
VERU vs XTNT Comparison
Compare VERU & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- XTNT
- Stock Information
- Founded
- VERU 1971
- XTNT N/A
- Country
- VERU United States
- XTNT United States
- Employees
- VERU N/A
- XTNT N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERU Health Care
- XTNT Health Care
- Exchange
- VERU Nasdaq
- XTNT Nasdaq
- Market Cap
- VERU 85.5M
- XTNT 82.1M
- IPO Year
- VERU 1990
- XTNT N/A
- Fundamental
- Price
- VERU $3.42
- XTNT $0.65
- Analyst Decision
- VERU Strong Buy
- XTNT
- Analyst Count
- VERU 3
- XTNT 0
- Target Price
- VERU $33.33
- XTNT N/A
- AVG Volume (30 Days)
- VERU 120.2K
- XTNT 62.7K
- Earning Date
- VERU 08-12-2025
- XTNT 11-11-2025
- Dividend Yield
- VERU N/A
- XTNT N/A
- EPS Growth
- VERU N/A
- XTNT N/A
- EPS
- VERU N/A
- XTNT N/A
- Revenue
- VERU $16,886,419.00
- XTNT $127,766,000.00
- Revenue This Year
- VERU N/A
- XTNT $13.03
- Revenue Next Year
- VERU N/A
- XTNT N/A
- P/E Ratio
- VERU N/A
- XTNT N/A
- Revenue Growth
- VERU 337.24
- XTNT 15.16
- 52 Week Low
- VERU $2.64
- XTNT $0.33
- 52 Week High
- VERU $14.20
- XTNT $0.78
- Technical
- Relative Strength Index (RSI)
- VERU 43.02
- XTNT 55.92
- Support Level
- VERU $3.40
- XTNT $0.59
- Resistance Level
- VERU $3.68
- XTNT $0.67
- Average True Range (ATR)
- VERU 0.22
- XTNT 0.04
- MACD
- VERU 0.08
- XTNT 0.00
- Stochastic Oscillator
- VERU 27.78
- XTNT 54.55
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.